[
    [
        {
            "time": "2020-11-16",
            "original_text": "【爱美客|事件点评】利拉鲁肽注射液获临床批件，减肥（重）领域布局增量可期【安信医药马帅团队】",
            "features": {
                "keywords": [
                    "利拉鲁肽",
                    "注射液",
                    "临床批件",
                    "减肥",
                    "增量"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【爱美客|事件点评】利拉鲁肽注射液获临床批件，减肥（重）领域布局增量可期【安信医药马帅团队】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-11-16",
            "original_text": "迈瑞医疗年内遭神秘股东三度减持，医疗器械不如医药“香”？ 减持股份数量较大。",
            "features": {
                "keywords": [
                    "迈瑞医疗",
                    "减持",
                    "医疗器械",
                    "医药"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "迈瑞医疗年内遭神秘股东三度减持，医疗器械不如医药“香”？ 减持股份数量较大。",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-11-16",
            "original_text": "恒瑞医药：子公司SHR-1314注射液临床试验获国家药监局批准",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "SHR-1314",
                    "注射液",
                    "临床试验",
                    "药监局批准"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药：子公司SHR-1314注射液临床试验获国家药监局批准",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-11-16",
            "original_text": "君实生物医保谈判前夕遭狙击？前三季亏损11亿元",
            "features": {
                "keywords": [
                    "君实生物",
                    "医保谈判",
                    "亏损"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "君实生物医保谈判前夕遭狙击？前三季亏损11亿元",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-11-16",
            "original_text": "4200亿医疗巨头怎么了？神秘股东三度减持，7天跌去750亿，更遭机构资金连续大甩卖，基金抱团开始松动？",
            "features": {
                "keywords": [
                    "医疗巨头",
                    "减持",
                    "机构资金",
                    "基金抱团"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "4200亿医疗巨头怎么了？神秘股东三度减持，7天跌去750亿，更遭机构资金连续大甩卖，基金抱团开始松动？",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        }
    ]
]